# Phio Pharmaceuticals Corp. (PHIO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $6M  
**Price:** $1.06 (-1.85%)

> Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics aimed at treating cancer. The company's primary goal is to leverage its proprietary self-delivering RNAi (sd-rxRNA) technology, designed to advance immune responses against cancer by enhancing the activation and persistence of immune cells. This innovative platform is central to its efforts in creating treatments that improve the efficacy of existing cancer therapies or standalone applications. Phio Pharmaceuticals Corp. is actively engaged in research and development, and its initiatives predominantly impact the biotechnology and healthcare sectors. Based in Marlborough, Massachusetts, the company plays a significant role in the ongoing efforts to find novel solutions to combat challenging cancer types, positioning itself as a key player in immunotherapy advancements. By collaborating with other biotech firms and healthcare institutions, Phio Pharmaceuticals aims to bring effective, trailblazing medicines to market, which could significantly alter the landscape of cancer treatment.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2020 | — | — | -$9M | -$9M | — |
| 2019 | $21,000 | — | -$9M | -$9M | — |
| 2018 | $138,000 | — | -$7M | -$7M | — |
| 2017 | $15,000 | — | -$14M | -$12M | — |
| 2016 | $19,000 | — | -$9M | -$9M | — |
| 2015 | $34,000 | — | -$10M | -$10M | — |
| 2013 | $399,000 | — | -$21M | -$21M | — |
| 2012 | $97,000 | — | -$13M | -$13M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2020 | $16M | $3M | $13M | — | $231,000 |
| 2019 | $8M | $2M | $6M | — | — |
| 2018 | $15M | $2M | $14M | — | — |
| 2017 | $4M | — | $2M | $4M | — |
| 2016 | $13M | — | $11M | $13M | — |
| 2015 | $11M | — | $9M | $5M | — |
| 2013 | $15M | $2M | $5M | $11M | — |
| 2012 | $6M | $2M | -$6M | $5M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$8M | $12,000 | -$8M |
| 2024 | -$7M | $1,000 | -$7M |
| 2023 | -$11M | $5,000 | -$11M |
| 2022 | -$12M | $121,000 | -$12M |
| 2021 | -$12M | $51,000 | -$12M |
| 2020 | -$9M | $19,000 | -$9M |
| 2019 | -$9M | $72,000 | -$9M |
| 2018 | -$8M | $5,000 | -$8M |
| 2017 | -$10M | $203,000 | -$10M |
| 2013 | -$6M | $78,000 | -$6M |
| 2012 | -$5M | $15,000 | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/PHIO)